Top

Published in:

Open Access 21-08-2023 | Oligodendroglioma | Research

Long-term follow up of patients with WHO grade 2 oligodendroglioma

Authors: Louise Carstam, Francesco Latini, Ole Solheim, Jiri Bartek Jr., Lars K. Pedersen, Maria Zetterling, Stanislav Beniaminov, Kristin Sjåvik, Mats Ryttlefors, Margret Jensdottir, Bertil Rydenhag, Anja Smits, Asgeir S. Jakola

Published in: Journal of Neuro-Oncology | Issue 1/2023

Abstract

Purpose

Since the introduction of the molecular definition of oligodendrogliomas based on isocitrate dehydrogenase (IDH)-status and the 1p19q-codeletion, it has become increasingly evident how this glioma entity differs much from other diffuse lower grade gliomas and stands out with longer survival and often better responsiveness to adjuvant therapy. Therefore, apart from using a molecular oligodendroglioma definition, an extended follow-up time is necessary to understand the nature of this slow growing, yet malignant condition. The aim of this study was to describe the long-term course of the oligodendroglioma disease in a population-based setting and to determine which factors affect outcome in terms of survival.

Methods

All adults with WHO-grade 2 oligodendrogliomas with known 1p19q-codeletion from five Scandinavian neurosurgical centers and with a follow-up time exceeding 5 years, were analyzed regarding survival and factors potentially affecting survival.

Results

126 patients diagnosed between 1998 and 2016 were identified. The median follow-up was 12.0 years, and the median survival was 17.8 years (95% CI 16.0–19.6).

Factors associated with shorter survival in multivariable analysis were age (HR 1.05 per year; CI 1.02–1.08, p < 0.001), tumor diameter (HR 1.05 per millimeter; CI 1.02–1.08, p < 0.001) and poor preoperative functional status (KPS < 80) (HR 4.47; CI 1.70–11.78, p = 0.002). In our material, surgical strategy was not associated with survival.

Conclusion

Individuals with molecularly defined oligodendrogliomas demonstrate long survival, also in a population-based setting. This is important to consider for optimal timing of therapies that may cause long-term side effects. Advanced age, large tumors and poor function before surgery are predictors of shorter survival.

Graphical Abstract

Available only for authorised users

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106CrossRefPubMedPubMedCentral

Rincon-Torroella J, Rakovec M, Materi J et al (2022) Current and future frontiers of molecularly defined oligodendrogliomas. Front Oncol 12:934426. https://doi.org/10.3389/fonc.2022.934426CrossRefPubMedPubMedCentral

Albuquerque LAF, Almeida JP, de Macêdo Filho LJM, Joaquim AF, Duffau H (2021) Extent of resection in diffuse low-grade gliomas and the role of tumor molecular signature—a systematic review of the literature. Neurosurg Rev 44(3):1371–1389. https://doi.org/10.1007/s10143-020-01362-8CrossRefPubMed

Booth CM, Eisenhauer EA (2012) Progression-free survival: Meaningful or simply measurable? J Clin Oncol 30(10):1030–1033. https://doi.org/10.1200/jco.2011.38.7571CrossRefPubMed

Gyawali B, Eisenhauer E, Tregear M, Booth CM (2022) Progression-free survival: it is time for a new name. Lancet Oncol 23(3):328–330. https://doi.org/10.1016/s1470-2045(22)00015-8CrossRefPubMed

Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. https://doi.org/10.1056/NEJMoa1308573CrossRefPubMedPubMedCentral

Mair MJ, Geurts M, van den Bent MJ, Berghoff AS (2021) A basic review on systemic treatment options in WHO grade II–III gliomas. Cancer Treat Rev 92:10224. https://doi.org/10.1016/j.ctrv.2020.102124CrossRef

Scherer M, Ahmeti H, Roder C et al (2020) Surgery for diffuse WHO Grade II gliomas: volumetric analysis of a multicenter retrospective cohort from the German study group for intraoperative magnetic resonance imaging. Neurosurgery 86(1):E64-e74. https://doi.org/10.1093/neuros/nyz397CrossRefPubMed

Achey RL, Khanna V, Ostrom QT, Kruchko C, Barnholtz-Sloan JS (2017) Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. J Neurooncol 133(1):17–25. https://doi.org/10.1007/s11060-017-2414-zCrossRefPubMed

10.

Hervey-Jumper SL, Zhang Y, Phillips JJ et al (2023) Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma. J Clin Oncol. https://doi.org/10.1200/jco.21.02929CrossRefPubMed

11.

Sawaya R, Hammoud M, Schoppa D et al (1998) Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42(5):1044–1055. https://doi.org/10.1097/00006123-199805000-00054 (Discussion 1055–6)CrossRefPubMed

12.

Jakola AS, Skjulsvik AJ, Myrmel KS et al (2017) Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 28(8):1942–1948. https://doi.org/10.1093/annonc/mdx230CrossRefPubMedPubMedCentral

13.

Ferreyra Vega S, Olsson Bontell T, Corell A, Smits A, Jakola AS, Carén H (2021) DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. Clin Epigenetics 13(1):102. https://doi.org/10.1186/s13148-021-01085-7CrossRefPubMedPubMedCentral

14.

Carstam L, Corell A, Smits A et al (2021) WHO grade loses its prognostic value in molecularly defined diffuse lower-grade gliomas. Front Oncol 11:803975. https://doi.org/10.3389/fonc.2021.803975CrossRefPubMed

15.

Carstam L, Rydén I, Jakola AS (2022) Seizures in patients with IDH-mutated lower grade gliomas. J Neurooncol 160(2):403–411. https://doi.org/10.1007/s11060-022-04158-6CrossRefPubMedPubMedCentral

16.

Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20(1):66–77. https://doi.org/10.1093/neuonc/nox132CrossRefPubMed

17.

Kavouridis VK, Boaro A, Dorr J et al (2019) Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis. J Neurosurg. https://doi.org/10.3171/2019.6.Jns19972CrossRefPubMedPubMedCentral

18.

Bush NAO, Young JS, Zhang Y et al (2021) A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. J Neurooncol 153(3):447–454. https://doi.org/10.1007/s11060-021-03781-zCrossRefPubMedPubMedCentral

19.

Latini F, Fahlström M, Hesselager G, Zetterling M, Ryttlefors M (2020) Differences in the preferential location and invasiveness of diffuse low-grade gliomas and their impact on outcome. Cancer Med 9(15):5446–5458. https://doi.org/10.1002/cam4.3216CrossRefPubMedPubMedCentral

20.

Skjulsvik AJ, Bø HK, Jakola AS et al (2020) Is the anatomical distribution of low-grade gliomas linked to regions of gliogenesis? J Neurooncol 147(1):147–157. https://doi.org/10.1007/s11060-020-03409-8CrossRefPubMedPubMedCentral

21.

Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19):1473–1479. https://doi.org/10.1093/jnci/90.19.1473CrossRefPubMed

22.

Wesseling P, van den Bent M, Perry A (2015) Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol 129(6):809–827. https://doi.org/10.1007/s00401-015-1424-1CrossRefPubMedPubMedCentral

23.

Garton ALA, Kinslow CJ, Rae AI et al (2020) Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas. J Neurosurg 134(5):1357–1367. https://doi.org/10.3171/2020.2.Jns192767CrossRefPubMed

24.

Iorgulescu JB, Torre M, Harary M et al (2019) The misclassification of diffuse gliomas: rates and outcomes. Clin Cancer Res 25(8):2656–2663. https://doi.org/10.1158/1078-0432.Ccr-18-3101CrossRefPubMedPubMedCentral

25.

Brat DJ, Verhaak RG, Aldape KD et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372(26):2481–2498. https://doi.org/10.1056/NEJMoa1402121CrossRefPubMed

26.

Delev D, Heiland DH, Franco P et al (2019) Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system. J Neurooncol 141(1):223–233. https://doi.org/10.1007/s11060-018-03030-wCrossRefPubMed

27.

Kawaguchi T, Sonoda Y, Shibahara I et al (2016) Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol 129(3):505–514. https://doi.org/10.1007/s11060-016-2201-2CrossRefPubMed

28.

Lin AJ, Kane LT, Molitoris JK et al (2020) A multi-institutional analysis of clinical outcomes and patterns of care of 1p/19q codeleted oligodendrogliomas treated with adjuvant or salvage radiation therapy. J Neurooncol 146(1):121–130. https://doi.org/10.1007/s11060-019-03344-3CrossRefPubMed

29.

Lu VM, Alvi MA, Bydon M, Quinones-Hinojosa A, Chaichana KL (2019) Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: insights from a national cancer registry. Clin Neurol Neurosurg 182:32–36. https://doi.org/10.1016/j.clineuro.2019.04.027CrossRefPubMed

30.

Patel SH, Bansal AG, Young EB et al (2019) Extent of surgical resection in lower-grade gliomas: differential impact based on molecular subtype. AJNR Am J Neuroradiol 40(7):1149–1155. https://doi.org/10.3174/ajnr.A6102CrossRefPubMedPubMedCentral

31.

Weller J, Katzendobler S, Karschnia P et al (2021) PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. J Neurooncol 153(2):283–291. https://doi.org/10.1007/s11060-021-03765-zCrossRefPubMedPubMedCentral

32.

Wijnenga MMJ, French PJ, Dubbink HJ et al (2018) The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol 20(1):103–112. https://doi.org/10.1093/neuonc/nox176CrossRefPubMed

33.

Yeboa DN, Yu JB, Liao E et al (2019) Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas. Clin Transl Radiat Oncol 15:46–52. https://doi.org/10.1016/j.ctro.2018.12.003CrossRefPubMed

34.

Harary M, Kavouridis VK, Torre M et al (2020) Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas. Neuro Oncol 22(3):369–380. https://doi.org/10.1093/neuonc/noz168CrossRefPubMed

35.

Kinslow CJ, Garton ALA, Rae AI et al (2019) Extent of resection and survival for oligodendroglioma: a US population-based study. J Neurooncol 144(3):591–601. https://doi.org/10.1007/s11060-019-03261-5CrossRefPubMed

36.

Garnier L, Vidal C, Chinot O et al (2022) Characteristics of anaplastic oligodendrogliomas short-term survivors: a POLA network study. Oncologist 27(5):414–423. https://doi.org/10.1093/oncolo/oyac023CrossRefPubMedPubMedCentral

37.

Halani SH, Yousefi S, Velazquez Vega J et al (2018) Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol 2:24. https://doi.org/10.1038/s41698-018-0067-9CrossRefPubMedPubMedCentral

38.

Darvishi P, Batchala PP, Patrie JT et al (2020) Prognostic value of preoperative MRI metrics for diffuse lower-grade glioma molecular subtypes. AJNR Am J Neuroradiol 41(5):815–821. https://doi.org/10.3174/ajnr.A6511CrossRefPubMedPubMedCentral

39.

Jakola AS, Pedersen LK, Skjulsvik AJ, Myrmel K, Sjåvik K, Solheim O (2022) The impact of resection in IDH-mutant WHO grade 2 gliomas: a retrospective population-based parallel cohort study. J Neurosurg. https://doi.org/10.3171/2022.1.Jns212514CrossRefPubMedPubMedCentral

40.

Alattar AA, Brandel MG, Hirshman BR et al (2017) Oligodendroglioma resection: a surveillance, epidemiology, and end results (SEER) analysis. J Neurosurg. https://doi.org/10.3171/2016.11.JNS161974CrossRefPubMed

41.

Jin K, Zhang SY, Li LW et al (2021) Prognosis of oligodendroglioma patients stratified by age: a SEER population-based analysis. Int J Gen Med 14:9523–9536. https://doi.org/10.2147/ijgm.S337227CrossRefPubMedPubMedCentral

42.

Lawrie TA, Gillespie D, Dowswell T et al (2019) Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma. Cochrane Datab Syst Rev 8(8):CD013047. https://doi.org/10.1002/14651858.CD013047.pub2CrossRef

43.

Kirkman MA, Hunn BHM, Thomas MSC, Tolmie AK (2022) Influences on cognitive outcomes in adult patients with gliomas: a systematic review. Front Oncol 12:943600. https://doi.org/10.3389/fonc.2022.943600CrossRefPubMedPubMedCentral

44.

Douw L, Klein M, Fagel SS et al (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8(9):810–818. https://doi.org/10.1016/s1474-4422(09)70204-2CrossRefPubMed

45.

Ahmad H, Martin D, Patel SH et al (2019) Oligodendroglioma confers higher risk of radiation necrosis. J Neurooncol 145(2):309–319. https://doi.org/10.1007/s11060-019-03297-7CrossRefPubMed

Title: Long-term follow up of patients with WHO grade 2 oligodendroglioma
Authors: Louise Carstam
Francesco Latini
Ole Solheim
Jiri Bartek Jr.
Lars K. Pedersen
Maria Zetterling
Stanislav Beniaminov
Kristin Sjåvik
Mats Ryttlefors
Margret Jensdottir
Bertil Rydenhag
Anja Smits
Asgeir S. Jakola
Publication date: 21-08-2023
Publisher: Springer US
Keywords: Oligodendroglioma
Glioma
Glioma
Glioma
Published in: Journal of Neuro-Oncology / Issue 1/2023
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04368-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long-term follow up of patients with WHO grade 2 oligodendroglioma

Abstract

Purpose

Methods

Results

Conclusion

Graphical Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

First in-human intrathecal delivery of bevacizumab for leptomeningeal spread from recurrent glioblastoma: rationale for a dose escalation trial

Effect of race, sex, and socioeconomic factors on overall survival following the resection of intramedullary spinal cord tumors

PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort

Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay

Molecular predictors for decitabine efficacy in meningiomas – a pilot study

Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial